Lindynette 30

Ethinylestradiol, the active ingredient in Lindynette 30, is a combined oral contraceptive presented as a tablet for oral use. It is formulated with gestodene, a progestogenic agent, to prevent pregnancy and to help regulate the menstrual cycle in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH USA supplies Lindynette 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets, providing reliable supply chain management.

Lindynette 30, a combined oral contraceptive, is used in the hormonal contraception pathway to prevent pregnancy and manage menstrual cycle disorders.

- Prevention of pregnancy: provides reliable contraceptive protection by suppressing ovulation. - Regulation of menstrual cycle: helps achieve more predictable bleeding patterns and reduces cycle irregularities. - Management of dysmenorrhea: may lessen menstrual pain through hormonal stabilization.

Lindynette 30 may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or discomfort. - Headache: occasional mild to moderate pain. - Weight gain: slight increase in body weight.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Hypertension: significant increase in blood pressure. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Liver dysfunction: abnormal liver enzyme levels or jaundice.

Before prescribing Lindynette 30, clinicians should consider several safety aspects.

- Cardiovascular risk assessment: evaluate history of thromboembolic events or smoking. - Liver function monitoring: avoid use in active liver disease. - Migraine evaluation: caution in patients with migraine with aura. - Breast cancer screening: contraindicated in known or suspected hormone‑sensitive cancers. - Smoking status: advise cessation, especially in women over 35. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Lindynette 30 can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may increase clotting risk.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole, itraconazole): can raise hormone levels, increasing side‑effect risk. - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly lower contraceptive effectiveness. - Herbal supplements (e.g., St. John’s wort): may reduce plasma concentrations of the active hormones.